secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-07-01T23:59:59+00:00
Accession:  0001193125-22-187190
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics grants CEO $254K cash + $508K RSU, CFO $168K cash + $336K RSU retention awards
--------------------------------------------------------------------------------

- CEO Ankit Mahadevia receives $254K cash bonus (Nov 30, 2022) and up to $508K in stock based on performance criteria.
- CFO Satyavrat Shukla receives $168K cash bonus (Nov 30, 2022) and up to $336K in stock based on performance criteria.
- Awards tied to continued employment through May 31, 2023 and achievement of pipeline, BD, and financial stewardship goals.
- Unvested RSUs lapse if performance criteria not met by May 31, 2023; vesting acceleration only in certain change-in-control events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522187190/0001193125-22-187190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522187190/d726728d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-187190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer